The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats

Archives of Medical Science

Volumn 7, Issue 3, 2011, Pages 405-413

  Gao, Xiwen ^a   Huang, Yi ^b   Han, Yipin ^b   Bai, Chun Xue ^c   Wang, Guifang ^c  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Ambroxol; Bronchoalveolar lavage; Pneumonia; Pseudomonas aeruginosa; Pulmonary surfactant

Indexed keywords

AMBROXOL; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUNG SURFACTANT; PHOSPHOLIPID; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; LAMELLAR BODY; LUNG ALVEOLUS CELL; LUNG LAVAGE; LUNG STRUCTURE; NEUTROPHIL; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RAT;

EID: 79960472381     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.23403     Document Type: Article

References (34)

1. Fagon JY, Chastre J, Domart Y, Trouillet JL, Gibert C. Mortality due to ventilated-associated pneumonia or colonization with pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996; 23: 538-42. (Pubitemid 26304504)
2. Ye F, Zhong SP, Yuan JP. Serial five-year-surveillance of resistant-rate of Gram-negative bacilli isolated from patients' lower airway tract in respiratory intensive care unit. Anti-infect Chemother Acta 2007; 7: 367-71. (Pubitemid 350011427)
3. Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J. Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia. Intensive Care Med 2006; 32: 1970-8. (Pubitemid 44833110)
4. Gillis RJ, White KG, Choi KH, Wagner VE, Schweizer HP, Iglewski BH. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2005; 49: 3858-67. (Pubitemid 41233042)
5. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-8. (Pubitemid 36254223)
6. Vanderzwan J, McCaig L, Mehta S, et al. Characterizing alterations in the pulmonary surfactant system in rat model of Pseudomonas aeruginosa pneumonia. Eur Respir J 1998; 12: 1388-96. (Pubitemid 29011435)
7. Baughman RP, Sternberg RI, Hull W, Buchsbaum JA, Whitsett J. Decreased surfactant protein A in patients with bacterial pneumonia. Am Rev Respir Dis 1993; 147: 653-7. (Pubitemid 23072657)
8. Günther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996; 153: 176-84. (Pubitemid 26026846)
9. Schmidt R, Meier U, Yabut-Perez M, et al. Alteration of fatty acid profiles in different pulmonary surfactant phospholipidsin acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med 2001; 163: 95-100. (Pubitemid 32095259)
10. Jaeger KE, Kharazmi A, Hoiby N. Extracellular lipase of Pseudomonas aeruginosa: biochemical characterization and effect on human neutrophils and monocyte function in vitro. Microb Pathog 1991; 10: 173-82.
11. Sun B, Herting E, Curstedt T, Robertson B. Exogenous surfactant improves lung compliance and oxygenation in adult rats with meconium aspiration. J Appl Physiol 1994; 77: 1961-71. (Pubitemid 24322460)
12. van Kaam AH, Lachmann RA, Herting E, et al. Reducing atelectasis attenuates bacterial growth and translocation in experimental pneumonia. Am J Respir Crit Care Med 2005; 172: 141.
13. Zhu GF, Sun B, Niu SF, et al. Combined surfactant therapy and inhaled nitric oxide in rabbits with oleic acid-induced acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 158: 437-43. (Pubitemid 28378170)
14. Song GW, Robertson B, Curstedt T, Gan XZ, Huang WX. Surfactant treatment in experimental Escherichia Coli pneumonia. Acta Anaesthesiol Scand 1996; 40: 1154-60. (Pubitemid 26363280)
15. Sehgal SS, Ewing CK, Richards T, Taeusch HW. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Natl Med Assoc 1994; 86: 46-52.
16. Alberti A, Pettenazzo A, Enzi GB, et al. Uptake and degradation of Curosurf after tracheal administration to newborn and adult rabbits. Eur Respir J 1998; 12: 294-300. (Pubitemid 28389521)
17. Pfeifer S, Zissel G, Kienast K, Muller-Quernheim J. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol. Eur J Med Res 1997; 2: 129-32.
18. Seifart C, Clostermann U, Seifart U, et al. Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicol Appl Pharmacol 2005; 203: 27-35. (Pubitemid 40208363)
19. Post M, Batenburg JJ, Schuurmans EAJM, Oldenborg V, van der Molen AJ, van Golde LGM. The perfused rat lung as a model for studies on the formation of surfactant and the effect of ambroxol on this process. Lung 1983; 161: 349-59. (Pubitemid 13021113)
20. Bartlett GB. Phosphorous assay in column chromatography. J Biol Chem 1959; 234: 466-71.
21. Mason RJ, Nellenbogen J, Clements JA. Isolation of disaturated phosphatidylcholine with osmium tetroxide. J Lipid Res 1976; 17: 281-4.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
23. Vanderzwan J, McCaig L, Mehta S, et al. Characterizing alterations in the pulmonary surfactant system in rat model of Pseudomonas aeruginosa pneumonia. Eur Respir J 1998; 12: 1388-96. (Pubitemid 29011435)
24. Lema G, Dryja D, Vargas I, Enhorning G. Pseudomonas aeruginosa from patients with cystic fibrosis affects function of pulmonary surfatant. Pediatr Res 2000; 47: 121-6. (Pubitemid 30038901)
25. Wu H, Kuzmenko A, Wan S, et al. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003; 111: 1589-602. (Pubitemid 38063292)
26. Baughman RP, Stermberg RI, Hull W, Buchsbaum JA, Whitsett J. Dereased surfactant protein-A in patients with bacterial pneumonia. Am Rev Respir Dis 1993; 147: 653-7. (Pubitemid 23072657)
27. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J 2002; 19: 797-804.
28. Herting E, Gefeller O, Land M, et al. Surfactant treatment of neonate with respiratory failure and group B streptococcal infection. Pediatrics 2000; 106: 957-64.
29. Grassi C, Luisetti M, De Rose V, et al. Biochemical and functional changes in bronchoalveolar parameters induced by ambroxol treatment of chronic bronchitis. In: Pulmonary surfactant system. Cosmi E, Scarpelli E (eds.). Elsevier, Rome 1983; 361-70.
30. Post M, Batenburg JJ, Schuurmans EAJM, Oldenborg V, van der Molen AJ, van Golde LGM. The perfused rat lung as a model for studies on the formation of surfactant and the effect of ambroxol on this process. Lung 1983; 161: 349-59. (Pubitemid 13021113)
31. Von Vichert P, Bavendamm U, Von Teichmann M, et al. Increased incorporation of fatty acids into phospholipids of lungs and livers of rabbits under the influence of bromexine and ambroxol. Archiv Pharmacol 1977; 297: 269-73. (Pubitemid 8079428)
32. Fraschi. Effects of a mucolytic agent on the bioavaility of antibiotics in patients with chronic respiratory disease. Curr Therap Res 1997; 8: 5.
33. Winselk. Antioxidant and anti-inflammatory properties of amboxol. Pheumology 1992; 9: 461
34. Yang B, Yao DF, Ohuchi M, et al. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur Respir J 2002; 19: 952-8. (Pubitemid 34567912)